Drugs / GT300
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04963855 Comparator | Aug 2021 → Feb 2022 | Lewy body dementia | Generian Pharmaceuticals, Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GT300 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04963855 ↗ |
| Route | Oral | “SIngle oral dose” NCT04963855 ↗ |